Inhibikase Therapeutics, Inc.
Income Statement
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $0 | $260.5K | $123.4K | $3.1M | $698.5K |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Gross Margin | — | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | $17.2M | $13.6M | $12.0M | $11.4M | $893.8K |
| SG&A Expense | $11.4M | $6.7M | $6.2M | $6.5M | $2.6M |
| Operating Income | $-28.6M | $-20.1M | $-18.1M | $-14.8M | $-2.8M |
| Operating Margin | — | -7,712.0% | -14,686.2% | -476.2% | -403.5% |
| Interest Expense | — | — | — | $19.9K | $29.4K |
| Pretax Income | $-27.5K | — | — | — | — |
| Income Tax Expense | $0 | — | — | — | — |
| Net Income | $-27.5M | $-19.0M | $-18.1M | $-14.8M | $-2.8M |
| Net Margin | — | -7,304.7% | -14,625.9% | -476.9% | -407.7% |
| EPS (Basic) | $-0.29 | $-0.20 | $-0.27 | $-0.05 | $-0.02 |
| EPS (Diluted) | $-0.29 | $-0.20 | $-0.27 | $-0.05 | $-0.02 |
| Shares Outstanding (Basic) | 94.8M | 96.5M | 67.6M | 291.3M | 160.8M |
| Shares Outstanding (Diluted) | 94.8M | 96.5M | 67.6M | 291.3M | 160.8M |
| Dividends Per Share | — | — | — | — | — |